Synapsoft logo
AI Insights from Disclosures
Searching...
Y-Biologics, Inc 338840
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Y-Biologics, Inc is a company that secures various antibody drug candidates based on one of the best antibody discovery platform technologies in South Korea, and either independently develops antibody therapeutics or jointly develops advanced biopharmaceuticals by combining its technology with partner companies' platform technologies. The company currently has a total of five pipelines under independent development, consisting of various immuno-oncology new drug candidates: (1) Acriksolimab (YBL-006), an immune checkpoint inhibitor targeting PD-1; (2) YBL-011, an immune checkpoint inhibitor targeting LAG-3; (3) AR062, an antibody therapeutic that targets CD39 to regulate the tumor microenvironment; (4) TGFβ Selectrap® (AR148), an antibody analog that targets TGFβ 1&3 to regulate the tumor microenvironment; and (5) AR092, a T cell engager bispecific antibody therapeutic.
Representative Director 박영우, 박범찬(각자대표)
Founded December 31, 2007
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 16011-0235641
Business number 314-81-95083
Phone Number 042-867-9971
Fax Number 042-867-9970
Website ybiologics.com
Company Address 대전광역시 유성구 테크로 4로 17, 비715호
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant